CLEC4C

From WikiMD's Medical Encyclopedia

Revision as of 05:49, 17 March 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

CLEC4C (C-type Lectin Domain Family 4 Member C), also known as BDCA-2 (Blood Dendritic Cell Antigen 2), is a protein that in humans is encoded by the CLEC4C gene. This protein is a member of the C-type lectin/C-type lectin-like domain (CTLD) superfamily. CLEC4C is specifically expressed in plasmacytoid dendritic cells (pDCs), which are a specialized type of dendritic cells involved in antiviral responses and the production of interferons.

Function[edit]

CLEC4C plays a crucial role in the immune system. It is involved in the recognition of glycan structures on the surface of pathogens or apoptotic cells by pDCs. Upon binding to its ligands, CLEC4C inhibits the production of interferon-alpha (IFN-α) by pDCs, thus playing a regulatory role in the innate immune response. This inhibition is critical for maintaining immune homeostasis and preventing excessive inflammatory responses that could lead to autoimmune diseases.

Structure[edit]

The CLEC4C protein contains a single C-type lectin-like domain (CTLD) at its extracellular N-terminus, a transmembrane region, and a short cytoplasmic tail. The CTLD is responsible for ligand recognition and binding. The precise structure of CLEC4C and its ligands are subjects of ongoing research, aiming to understand the molecular basis of its function and regulation.

Clinical Significance[edit]

Given its role in modulating the immune response, CLEC4C is of interest in the study of autoimmune diseases, such as lupus erythematosus and psoriasis, where dysregulation of the immune system plays a critical role. Therapeutic targeting of CLEC4C, either by agonists or antagonists, could potentially modulate pDC activity and, thereby, the production of IFN-α, offering new avenues for the treatment of these conditions.

Additionally, the specific expression of CLEC4C on pDCs makes it a useful marker for the identification and study of this cell type in the context of disease and immunotherapy.

Research Directions[edit]

Research on CLEC4C is focused on elucidating its ligands and signaling pathways to better understand its role in immune regulation and its potential as a therapeutic target. Studies are also exploring the role of CLEC4C in the context of infections, cancer, and vaccination, where modulation of the immune response can have therapeutic benefits.

See Also[edit]

References[edit]

<references/>

External Links[edit]


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!


Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.